The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded, after conducting a quality review of the genetically engineered monoclonal antibody MabThera, that the batches of rituximab, the active substance of MabThera, that were produced in the U.S. at the Vacaville manufacturing site do not present a risk to public health...
Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/C9A_OlIa6gE/246011.php
news Massage St Albans">auto sport medical
No comments:
Post a Comment